Clinical Trials Logo

Advanced Melanoma clinical trials

View clinical trials related to Advanced Melanoma.

Filter by:

NCT ID: NCT01064713 Completed - Cancer Clinical Trials

Phase II Study of Tesetaxel in Metastatic Melanoma

Start date: February 2010
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if tesetaxel can help to control metastatic melanoma. The safety of this drug will also be studied.

NCT ID: NCT00920907 Completed - Advanced Melanoma Clinical Trials

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The purpose of this clinical research study is to compare pharmacokinetics of ipilimumab manufactured by two different processes

NCT ID: NCT00813449 Recruiting - Advanced Melanoma Clinical Trials

Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma

melanoma
Start date: August 2008
Phase: Phase 2
Study type: Interventional

Multicenter, double-blinding, randomized controlled, phase II clinical trial on combined chemotherapy of Endostar (Recombinant Human Endostatin) for untreated patients with advanced melanoma, To compare the efficacy and safety of Endostar combined with Dacarbazine and monotherapy of Dacarbazine for advanced melanoma

NCT ID: NCT00796991 Completed - Advanced Melanoma Clinical Trials

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

Start date: February 2009
Phase: Phase 1
Study type: Interventional

The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine

NCT ID: NCT00688090 Completed - Advanced Melanoma Clinical Trials

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Start date: June 2008
Phase: Phase 1
Study type: Interventional

A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.

NCT ID: NCT00667953 Terminated - Melanoma Clinical Trials

Study of Temzolomide and Gleevec in Advanced Melanoma

Start date: January 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients with melanoma.

NCT ID: NCT00542893 Completed - Advanced Melanoma Clinical Trials

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

Start date: April 2006
Phase: Phase 1
Study type: Interventional

This clinical drug-drug interaction study is being conducted to evaluate the pharmacokinetics of dacarbazine(DTIC) when administered in combination with Genasense

NCT ID: NCT00197912 Completed - Advanced Melanoma Clinical Trials

Dendritic Cell Based Therapy of Malignant Melanoma

Start date: September 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study is to show if vaccination with autologous dendritic cells pulsed with peptides or tumor lysate in combination with adjuvant cytokines and Cyclophosphamide can induce a measurable immune response in patients with metastatic malignant melanoma, and to evaluate the clinical effect (objective response rate) of the vaccination regime.